Analysts Set Cencora, Inc. (NYSE:COR) Target Price at $259.44

Cencora, Inc. (NYSE:COR) has received an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $259.44.

A number of equities research analysts have recently commented on COR shares. Leerink Partners cut their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Evercore ISI lowered their price target on Cencora from $270.00 to $250.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Bank of America reaffirmed a “neutral” rating and set a $245.00 price target (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Wells Fargo & Company upped their price target on Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. Finally, Robert W. Baird lowered their price target on Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a report on Friday, September 6th.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total value of $5,071,822.20. Following the transaction, the chairman now owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 15.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. New Millennium Group LLC bought a new position in shares of Cencora in the second quarter worth about $26,000. TCTC Holdings LLC bought a new position in shares of Cencora in the first quarter worth about $29,000. TFO Wealth Partners LLC bought a new position in shares of Cencora in the first quarter worth about $30,000. MFA Wealth Advisors LLC bought a new position in shares of Cencora in the second quarter worth about $30,000. Finally, Concord Wealth Partners bought a new position in shares of Cencora in the third quarter worth about $30,000. Institutional investors own 97.52% of the company’s stock.

Cencora Trading Down 0.2 %

NYSE COR opened at $233.89 on Thursday. Cencora has a 12 month low of $191.11 and a 12 month high of $247.66. The stock has a market cap of $46.09 billion, a P/E ratio of 25.40, a P/E/G ratio of 1.45 and a beta of 0.44. The stock’s fifty day moving average price is $231.38 and its 200-day moving average price is $230.57. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.